COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01755390
Recruitment Status : Completed
First Posted : December 24, 2012
Last Update Posted : December 24, 2012
Information provided by (Responsible Party):

Brief Summary:

Primary Objective:

- To determine the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of XRP6258 when given as a weekly 1-hour intravenous (i.v.) infusion for the first 4 consecutive weeks of each 5-week treatment cycle (Day 1, Day 8, Day 15, Day 22 of each 5-week treatment cycle).

Secondary Objectives :

  • To define the safety profile of the drug
  • To establish the recommended dose and time interval for future Phase II trials
  • To determine the pharmacokinetic (PK) profile of XRP6258 in man
  • To assess the absolute oral bioavailability of XRP6258 at the i.v. recommended dose (following Protocol Amendment No. 2)
  • To look for evidence of antitumor activity

Condition or disease Intervention/treatment Phase
Advanced Solid Tumor Drug: Cabazitaxel (XRP6258) Phase 1

Detailed Description:

The duration of the study will include the following periods:

  • Pretreatment: 28 to 7 days before first infusion
  • Treatment: Weekly for the first four consecutive weeks during 5-week treatment cycle
  • Post-treatment: 3 - 4 weeks after last infusion.

Treatment may be continued until disease progression or unacceptable toxicity or patient refusal.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Dose Finding Study of XRP6258 Administered as a Weekly 1-hour Intravenous Infusion to Patients With Advanced Solid Tumors
Study Start Date : October 1999
Actual Primary Completion Date : August 2002
Actual Study Completion Date : October 2002

Resource links provided by the National Library of Medicine

Drug Information available for: Cabazitaxel

Arm Intervention/treatment
Experimental: Cabazitaxel

IV escalation part:

XRP6258 administered as a 1-hour IV infusion on Days 1, 8, 15 and 22 of each 5-week cycle until evidence of disease progression, unacceptable toxicity or patient's withdrawal.

Oral bioavailability part:

XRP6258 administered at the dose of 8.4 mg/m² as an oral administration on Day 1 Cycle 1 and as a weekly 1-hour i.v. infusion at the subsequent weeks of treatment. Patients receiving oral administration at Day 1, Cycle 1 are to fast for 12 hours before and 4 hours after administration.

Drug: Cabazitaxel (XRP6258)
Pharmaceutical form: infusion solution Route of administration: Intravenous
Other Name: Jevtana

Primary Outcome Measures :
  1. Dose-limiting toxicity [ Time Frame: Up to 35 months ]
  2. Maximum tolerated dose [ Time Frame: Up to 35 months ]

Secondary Outcome Measures :
  1. Number of patients with adverse events [ Time Frame: Up to 35 months ]
  2. Antitumor activity [ Time Frame: Up to 35 months ]
    Measured by X-ray, ultrasound and/or scans

  3. Pharmacokinetic parameters including Cmax, AUC(0-t), AUC, t, t1/2λz (h), Vss, CL, accumulation ratio, Tmax metabolite ratio and F (bioavailability) [ Time Frame: Up to 35 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Signed informed consent prior to beginning protocol specific procedures
  2. Histologically proven cancer at the first diagnosis. At study entry, it was desirable but not required to have histological or cytological proof of metastasis in the case of a 1 single metastatic target lesion.
  3. Advanced neoplastic disease that was refractory to conventional treatment or for which no standard therapy existed
  4. Progressive disease
  5. Age 18-70 years
  6. ECOG (Eastern Cooperative Oncology Group) performance status of 0 to 2
  7. Off previous anticancer (radio- or chemo-) therapy for at least 4 weeks and 6 weeks if prior nitrosoureas, mitomycin C; recovery from the toxic effects of prior treatment (Grade ≤1, except alopecia any grade)
  8. Off previous immunotherapy for at least 1 week provided that patients did not have any residual signs of any toxicity
  9. Adequate organ function including: neutrophils ≥2.0 × 109/L; platelets ≥100 × 109/L, creatinine <120 μmol/L (if borderline creatinine values, the creatinine clearance had to be ≥60 mL/min); total bilirubin within normal limit; alanine aminotransferase (ALT)/aspartate aminotransferase (AST)/alkaline phosphatase (ALP) ≤2.5-fold the upper normal limits of the institutional norms (ALP ≤2.5 UNL)
  10. Patients registered in this trial had to be treated and followed at the participating centers
  11. Patients who had received previous treatment with paclitaxel or docetaxel could be included provided that they did not have any residual signs of taxane toxicity (except alopecia any grade and peripheral neuropathy Grade 1)

Exclusion Criteria:

  1. Hematological malignancies
  2. Pregnant or lactating women or women of childbearing potential (eg, not using adequate contraception)
  3. Symptomatic brain metastases
  4. Previous extensive radiotherapy (>20% of bone marrow area)
  5. Current peripheral neuropathy of any origin including significant residual symptoms due to the use of eg, vinca-alkaloids or platinum ≥Grade 2 according to the National Cancer Institute common terminology criteria for adverse events.
  6. Other serious illness or medical conditions:

    • Congestive heart failure or angina pectoris even if medically controlled, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or arrhythmias
    • Existence of significant neurological or psychiatric disorders including dementia or seizures
    • Active infection
    • Uncontrolled peptic ulcer, unstable diabetes mellitus, or other contraindications for the use of corticosteroids
  7. Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to patient registration
  8. Concurrent treatment with any other anticancer therapy
  9. Concomitant radiotherapy
  10. Concomitant treatment with corticosteroids. However, patients receiving chronic treatment with corticosteroids (≤20 mg of methylprednisolone or ≤4 mg of dexamethasone or equivalent dose of other corticosteroids), for whatever reason, were eligible.
  11. More than 2 prior chemotherapy regimens containing mitomycin C or nitrosoureas
  12. More than 2 prior chemotherapy regimens for advanced disease
  13. Prior history of severe allergic reaction to docetaxel or paclitaxel
  14. Prior intensive chemotherapy with autologous stem cell rescue

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01755390

Layout table for location information
Paris, France
Barcelona, Spain
Sponsors and Collaborators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Sanofi Identifier: NCT01755390    
Other Study ID Numbers: TED6189
First Posted: December 24, 2012    Key Record Dates
Last Update Posted: December 24, 2012
Last Verified: December 2012
Additional relevant MeSH terms:
Layout table for MeSH terms